The best-established biomarkers for Alzheimer’s disease have a low natural variation over two years. The results speak for the inclusion of these biomarkers in clinical trials of novel drugs against Alzheimer’s disease. The results are presented by researchers at the Sahlgrenska Academy at Göteborg University, Sweden, in the November 2007 issue of the Journal of Alzheime’s Disease.
